Drugs that contain Enasidenib Mesylate
1. Idhifa patents expiration
IDHIFA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512107 | CELGENE CORP | Therapeutically active compositions and their methods of use |
Jan, 2033
(9 years from now) | |
| US10093654 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(10 years from now) | |
| US9738625 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(10 years from now) | |
| US9732062 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Sep, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | CELGENE CORP | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(6 years from now) | |
| US10294215 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Jan, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 1, 2024 |
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
More Information on Dosage
IDHIFA family patents
